The development of pancreatic cancer is characterized by an ongoing and fluctuating process that involves the aberrant expression of various biomolecules, including CA199, CEA, the P53 gene, the P16 gene, the urokinase-type plasminogen activator receptor (uPAR), mucin (muc), survivin, and plectin-1 [4,5]. This evidence concerns the gene BIRC5 and familial pancreatic carcinoma.